Modification of Human T-Cell Responses by Altered Peptide Ligands: A New Approach to Antigen-specific Modification

Internal Medicine

Volumn 37, Issue 10, 1998, Pages 804-817

  Nishimura, Yasuharu ^a   Chen, Yu Zhen ^a   Kanai, Takayuki ^a   Yokomizo, Hiroshi ^a   Matsuoka, Takako ^a   Matsushita, Sho ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Altered peptide ligands; Antigen presentation; Antigenic peptides; Cd4+ t cells; Human leukocyte antigen (hla)class ii molecule; T cell activation

Indexed keywords

ANTIGEN; AUTOANTIGEN; BACTERIAL ANTIGEN; BCL2L1 PROTEIN, HUMAN; BCL2L1 PROTEIN, MOUSE; CHOLINERGIC RECEPTOR; HLA D ANTIGEN; HRAS PROTEIN, HUMAN; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; LYMPHOKINE; PEPTIDE FRAGMENT; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; ANTIGEN PRESENTATION; APOPTOSIS; AUTOIMMUNE DISEASE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CELL CLONE; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; INFANT; LYMPHOCYTE ACTIVATION; MITE; MOLECULAR GENETICS; MOUSE; MYASTHENIA GRAVIS; MYCOBACTERIUM BOVIS; REVIEW; SECRETION; T LYMPHOCYTE SUBPOPULATION;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, BACTERIAL; APOPTOSIS; AUTOANTIGENS; AUTOIMMUNE DISEASES; BCL-X PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CLONE CELLS; HLA-D ANTIGENS; HUMANS; INFANT; LIGANDS; LYMPHOCYTE ACTIVATION; LYMPHOKINES; MICE; MITES; MOLECULAR SEQUENCE DATA; MYASTHENIA GRAVIS; MYCOBACTERIUM BOVIS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTE SUBSETS;

EID: 0032176307     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.804     Document Type: Article

References (96)

1. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation, in: Annual Review of Immunology, WE Paul, Fathman CG, Metzger H, Ed. Vol. 11, Annual Reviews Inc. Palo Alto, CA, 1993, p. 403-450.
2. Sette A, Sidney J, Oseroff C, et al. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol 151: 3163-3170, 1993.
3. Hammer J, Valsasnini P, Tolba K, et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74: 197-203, 1993.
4. Chicz, RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strommger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178: 27-47, 1993.
5. Matsushita S,Takahashi K, Motoki M, Komoriya K, Ikagawa S, Nishimura Y. Allele specificity of structural requirement for peptides bound to HLA- DRB 1*0405 and -DRB 1*0406 complexes: Implication for the HLA- associated susceptibility to methimazole-induced insulin autoimmune syndrome. J Exp Med 180: 873-883, 1994.
6. Hammer J, Gallazzi F, Bono E, et al. Peptide binding specificity of HLA- DR4 molecules: Correlation with rheumatoid arthritis association. J Exp Med 181: 1847-1855, 1995.
7. Brown JH, Jardetzky TS, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364: 33-39, 1993.
8. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378: 457-462, 1995.
9. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0401, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7: 473-481, 1997.
10. Stern LJ, Brown JH, Jardetzky TS, et al. Crystal structure of the human class II MHC protein HLA-DR 1 complexed with an influenza virus peptide Nature 368: 215-221, 1994.
11. Krieger JI, Karr RW, Grey HM, et al. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol 146: 2331-2340, 1991.
12. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252: 1308-1310, 1991.
13. Soloway P, Fish S, Passmore H, Gefter M, Coffee R, Manser T. Regulation of the immune response to peptide antigens: differential induction of immediate-type hypersensitivity and T cell proliferation due to changes in either peptide structure or major histocompatibility complex haplo-type. J Exp Med 174: 847-858, 1991.
14. De Magistris MT, Alexander J, Coggeshall M, et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68: 625-634, 1992.
15. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363: 156-159, 1993.
16. Ostrov D, Krieger J, Sidney J, Sette A, Concannon P. T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues. J Immunol 150: 4277-4283, 1993.
17. Alexander J, Snoke K, Ruppert J, et al. Functional consequences of engagement of the T cell receptor by low affinity ligands. J Immunol 150: 1-7, 1993.
18. Sloan-Lancaster J, Evavold BD, Allen PM. Th2 cell clonal anergy as a consequence of partial activation. J Exp Med 180: 1195-1205, 1994.
19. Windhagen A, Scholz C, Hollsberg P, Fukaura H, Sette A, Hafler DA. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 2: 373-380, 1995.
20. Chen YZ, Matsushita S, Nishimura Y. Response of an human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation. J Immunol 157: 3783-3790, 1996.
21. Ikagawa S, Matsushita S, Chen YZ, Ishikawa T, Nishimura Y. Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)- derived peptide induced alterations in human T cell responses and T cell receptor antagonism. J Allergy Clin Immunol 97: 53-64, 1996.
22. Matsuoka T, Kohrogi H, Ando M, Nishimura Y, Matsushita S. Altered TCR ligands affect APC responses: Upregulation of IL-12 by an analogue peptide. J Immunol 157: 4837-4843, 1996.
23. Matsushila S, Kohsaka H, Nishimura Y. Evidence for self- and non-self- peptide partial agonists that prolong clonal survival of mature T cells in vitro. J Immunol 158: 5685-5691, 1997.
24. Racioppi L, Ronchese F, Matis LA, Germain RN. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J Exp Med 177: 1047-1060, 1993.
25. 37 affects recognition of peptides by Tcells. Human Immunol 54: 30-39, 1997.
26. Sloan-Lancaster J, Shaw AS, Rothhard JB, Allen PM. Partial T cell signaling: altered phospho-ζ and lack of zap70 recruitment in APL- induced T cell anergy. Cell 79: 913-922, 1994.
27. Madrenas J, Wange RL, Wang JL, Isakov N, Samelson LE, Germain RN. ζ Phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 267: 515-518, 1995.
28. Sloan-Lancaster J, Steinberg TH, Allen PM. Selective activation of the calcium signaling pathway by altered peptide ligands. J Exp Med 184: 1525-1530, 1996.
29. Rabinowitz JD, Beeson C, Wulfing C,et al. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 5: 125-135, 1996.
30. Wulfing C, Rabinowitz JD, Beeson C, Sjaastad MD, McConnell HM, Davis MM. Kinetics and extent of T cell activation as measured with the calcium signal. J Exp Med 185: 1815-1825, 1997.
31. Lyons DS, Lieberman SA, Hampl J, et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 5: 53-61, 1996.
32. Uchigata Y, Omori Y, Nieda M, Kuwata S, Tokunaga K, Juji T. HLA- DR4 genotype and insulin-processing in insulin autoimmune syndrome. Lancet 340: 1467, 1992.
33. Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol 16: 519-534, 1984.
34. Levinson AI, Zweiman B, Lisak RP. Immunopathogenesis and treatment of myasthenia gravis. J Clin Immunol 7: 187-197, 1987.
35. Christadoss P. Immunogeneticsol experimental autoimmune myasthenia gravis. Crit Rev Immunol 9: 247-278, 1989.
36. Fukuyama Y, Hirayama Y, Osawa M. Myasthenia Gravis, Pathogenesis and Treatment. Japan Medical Research Foundation, University of Tokyo Press, Tokyo, 1981.
37. Audrey SP, Lewis PR. Myasthenia Gravis. In: Merrtt's Textbook of Neurology, Lewis PR, Ed. Ninth Edition, Williams & Wilkins, PA, 1995, p. 754-761.
38. Pirskanen R. On the significance of HL-A and LD antigens in myasthenia gravis. Ann N Y Acad Sci 274: 451-460, 1976.
39. Naeim F, Keesey JC, Herrmann C Jr, Lindstrom J, Zeller E, Walford RL. Association of HLA-B8, DRw 3, and anti-acetylcholine receptor antibodies in myasthenia gravis. Tissue Antigens 12: 381-386, 1978.
40. Matsuki K, Juji T, Tokunaga K, et al. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 86: 392-399, 1990.
41. Nomura Y, Ehara M, Matsuki K, Juji T, Segawa M. HLA haplotype in myasthenia gravis (MG) of Japanese children. Correlative studies between MG patients and their normal siblings and parents. Ann N Y Acad Sci 681: 581-583, 1993.
42. Raftery MA, Hunkapiller MW, Strader CD, Hood LE. Acetylcholine receptor: complex of homologous subunits. Science 208: 1454-1456, 1980.
43. Beeson D, Morris A, Vincent A, Newsom-Davis J. The human muscle nicotinic acetylcholine receptor alpha-subunit exist as two isoforms: a novel exon. EMBO J 9: 2101-2106, 1990.
44. Morris A, Beeson D, Jacobson L, Baggi F, Vincent A, Newsom-Davis J. Two isoforms of the muscle acetylcholine receptor alpha-subunit are translated in the human cell line TE671. FEBS Lett 295: 116-118, 1991.
45. Tzartos SJ, Kokla A, Walgrave SL, Conti-Tronconi BM. Localization of the main immunogenic region of human muscle acetylcholine receptor to residue 67-76 of the alpha subunit. Proc Natl Acad Sci USA 85: 2899-2903, 1988.
46. Moiola L, Protti Mp, Manfredi AA, Yuen MH, Howard JF Jr, Coti- Tronconi BM. T-helperepitopes on human nicotinic acetylcholine receptor in myasthenia gravis. Ann N Y Acad Sci 681: 198-218, 1993.
47. Willcox N, Baggi F, Batocchi AP, et al. Approaches for studying the pathogenic T cells in autoimmune patients. Am N Y Acad Sci 681: 219-237, 1993.
48. Manfredi AA, Protti MP, Dalton MW, Howard JF Jr, Conti-Tronconi BM. Thelpercell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits. J Clin Invest 92: 1055-1067, 1993.
49. + epitopes. J Immunol 152: 4686-4698, 1994.
50. Matsuo H, Batocchi AP, Hawke S, et al. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J Immunol 155: 3683-3692, 1995.
51. Kanai T, Nomura Y, Segawa M, et al. Immuno-suppressive peptides for a human T cell clone autoreactive to a unique acetylcholine receptor α subunit peptide presented by the disease susceptible HLA-DQ6 in infant- onset myasthenia gravis. Human Immunol 56: 28-38, 1997.
52. Ozdemirli M, el-Khatib M, Bastiani L, Akdeniz H, Kuchroo V, Ju ST. The cytotoxic process of CD4 Th1clones. J Immunol 149: 1889-1895, 1992.
53. + cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer 60: 802-807, 1995.
54. Bos JL. ras oncogenes in human cancer: a review Cancer Res 49: 4682-4689, 1989 (published erratum appears in Cancer Res Feb 50: 1352, 1990).
55. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173: 273-276, 1991.
56. Fossum B, Gedde-Dahl T, Hansen T, Eriksen JA, Thorsby E, Gaudernack G. Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur J Immunol 23: 2687-2691, 1993.
57. Gedde-Dahl T, fossum B, Eriksen JA, Thorsby E, Gaudernack G. T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur J Immunol 23: 754-760, 1993.
58. Van Elsas A, Nijman HW, Van der Minne CE, et al. Induction and characterization of cytotoxic T-lymphocytes recognizinga mutated p21 ras peptide presented by HLA-A*0201. Int J Cancer 61: 389-396, 1995.
59. Gedde-Dahl Td, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln → Leu61). Int Immunol 4: 1331-1337, 1992.
60. 13Gly → Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? Int J Cancer 58: 506-511, 1994.
61. 13Gly → Asp). Int J Cancer 56: 40-45, 1994.
62. Gjertsen MK, Bakka A, Breivik J, et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346: 1399-1400, 1995.
63. + T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 55: 2984-2987, 1995.
64. Fenton RG, Keller CJ, Hanna N, Taub DD. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J Natl Cancer Inst 87: 1853-1861, 1995.
65. d-restricted neo-antigen by a Tyr substitution. J Exp Med 174: 1657-1660, 1991.
66. Yokomizo H, Matsushita S, Fujisao S, et al. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides. Human Immunol 52: 22-32, 1997.
67. O'Sullivan D, Arrhenius T, Sidney J, et al. On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol 147: 2663-2669, 1991.
68. Hammer J, Takacs B, Sinigaglia F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med 176: 1007-1013, 1992.
69. + T cell lines reactive with a self-K-ras-derived peptide in vitro, using a mAb to CD29. Human Immunol 52: 179-182, 1998.
70. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146, 1996.
71. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient mice. Science 254: 707-710, 1991.
72. + T cells from allergic individuals. J Exp Med 178: 2123-2130, 1993.
73. + T cell clones. J Immunol 148: 738-745, 1992.
74. Ebner C, Szépfalusi Z, Ferreira F, et al. Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides. J Immunol 150: 1047-1054, 1993.
75. Joost van Neerven R, van H, Ringrose JH, et al. T cell epitopes of house dust mite major allergen Der p II. J Immunol 151: 2326-2335, 1993.
76. van Neerven RJ, van de Pol MM, van Milligan FJ, Jansen HM, Aalberse RC, Kapsenberg ML. Characterization of cat dander-specific T lymphocytes from atopic patients. J Immunol 152: 4203-4210, 1994.
77. Spiegelberg HL, Beck L, Stevenson DD, Ishioka GY. Recognition of T cell epitopes and lymphokine secretion by rye grass allergen Lolium perenne I-specitic human T cell clones. J Immunol 152: 4706-4711, 1994.
78. Matsuoka T, Kohrogi H, Ando M, Nishimura Y, Matsushita S. Dermatophagoides farinae-1-derived peptides and HLA molecules recognized by T cells from atopic individuals. Int Arch Allergy Immunol 112: 365-370, 1997.
79. + T cells in the thymus. Cell 73: 1041-1049, 1993.
80. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27, 1994.
81. Evavold BD, Sloan-Lancaster J, Wilson KJ, Rothbard JB, Allen PM. Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. Immunity 2: 655-663, 1995.
82. + T cells by a self-derived peptide. Nature 378: 295-298, 1995.
83. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell- mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80: 695-705, 1995.
84. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. HLA- DRB4*0101 -restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med 181: 1835-1845, 1995.
85. Barnes PF, Mehra V, Rivoire B, et al. Immunoreactivity of a 10-kDa antigen of Mycobacterium tuberculosis. J Immunol 148: 1835-1840, 1992.
86. +T cell repertoire recognizing one TCR ligand. Immunol Lett 51: 191-194, 1996.
87. Matsushita S, Nishimura Y. Partial activation of human T cells by peptide analogs on live APC: induction of clonal anergy associated with protein tyrosine dephosphorylation. Hum Immunol 53: 73-80, 1997.
88. Lee SW, Tomasetto C, Paul D, Keyomarsi K, Sager R. Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. J Cell Biol 118: 1213-1221, 1992.
89. Krenacs T, Rosendaal M. Immunohistological detection of gap junctions in human lymphoid tissues: connexin 43 in follicular dendritic and lymphoendothelial cells. J Histochem Cytochem 43: 1125-1137, 1995.
90. Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993.
91. + helper T cells. A model for the long-term survival of memory cells. J Immunol 156: 1764-1771, 1996.
92. L. Immunity 3: 87-98, 1995.
93. Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-dericient mice. Science 267: 1506-1510, 1995.
94. Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. Nature 369: 648-652, 1994.
95. Bruno L, Kirberg J, von Boehmer H. On the cellular basis of immunological T cell memory. Immunity 2: 37-43, 1995.
96. + T cells but affect their long-term life span. Immunity 5: 217-228, 1996.